Caliway Biopharmaceuticals Co Ltd

Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction

September 22, 2026

Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment

August 25, 2026

Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514

May 22, 2026

Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects

May 19, 2026

Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition

April 13, 2026

6919:TWSE

TW · TWD

Alternate listing for Caliway Biopharmaceuticals Co Ltd; the primary context on this page is CLBPF:OTC.